Scholarlink

<p>Breast cancer is the second most frequent malignancy in women and the fifth primary cause of cancer mortality globally. Although early identification and detection of breast cancer has resulted in decreased death rates, further breakthroughs in prevention, detection, and therapy are needed to enhance results and survival for women suffering from breast cancer, and also to provide a personalized therapeutic strategy Aside from the approximately 2% of the human genome that encodes proteins, a significant portion consists of non-coding RNA (ncRNA) which encompasses microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNA (circRNA), small nucleolar RNA (snoRNA), and PIWI-interacting RNAs (piRNA). So far, a substantial number of ncRNAs have been discovered and shown to be dysregulated in different forms of cancer, like breast cancer. Various modalities for detecting non-coding RNAs (ncRNAs) have been developed, including conventional northern blotting, microarrays, and reverse transcription-quantitative PCR (RT-qPCR). To overcome the structural constraints of these traditional methods, biosensor technologies have emerged as alternative platforms for the non-invasive, sensitive, and rapid quantification of oncogenic ncRNAs. Depending on the signal-transduction mechanism, these platforms are primarily categorized into electrochemical, optical, and field-effect transistor (FET)-based biosensors. This review provides a focused overview of recent advancements in ncRNA-targeted biosensing interfaces, evaluating their operational frameworks and challenges regarding breast cancer diagnosis and monitoring.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mechanism of detection breast cancer using biosensors based on non-coding RNA

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Monireh Motaqi,
  • Ardavan Shahbazi,
  • Reza Hosseinpour,
  • Farzaneh Karimi,
  • Mohammad Hashempour,
  • Seyed Mohammad Salehi Behbahani,
  • Ehsan Moradi-Joo,
  • Ahmad Movahedpour,
  • Hassan Ghasemi,
  • Sajad Ehtiati

摘要

Breast cancer is the second most frequent malignancy in women and the fifth primary cause of cancer mortality globally. Although early identification and detection of breast cancer has resulted in decreased death rates, further breakthroughs in prevention, detection, and therapy are needed to enhance results and survival for women suffering from breast cancer, and also to provide a personalized therapeutic strategy Aside from the approximately 2% of the human genome that encodes proteins, a significant portion consists of non-coding RNA (ncRNA) which encompasses microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNA (circRNA), small nucleolar RNA (snoRNA), and PIWI-interacting RNAs (piRNA). So far, a substantial number of ncRNAs have been discovered and shown to be dysregulated in different forms of cancer, like breast cancer. Various modalities for detecting non-coding RNAs (ncRNAs) have been developed, including conventional northern blotting, microarrays, and reverse transcription-quantitative PCR (RT-qPCR). To overcome the structural constraints of these traditional methods, biosensor technologies have emerged as alternative platforms for the non-invasive, sensitive, and rapid quantification of oncogenic ncRNAs. Depending on the signal-transduction mechanism, these platforms are primarily categorized into electrochemical, optical, and field-effect transistor (FET)-based biosensors. This review provides a focused overview of recent advancements in ncRNA-targeted biosensing interfaces, evaluating their operational frameworks and challenges regarding breast cancer diagnosis and monitoring.